Author:
Peipert John Devin,Shaunfield Sara,Kaiser Karen,Moreno Patricia I.,Fox Rina S.,Kircher Sheetal,Mohindra Nisha,Ip Edward,Zhao Fengmin,Wagner Lynne,Cella David
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human. Statistical principles for clinical trials. February 5th 1998. https://database.ich.org/sites/default/files/E9_Guideline.pdf. Accessed 25 Apr 2022
2. Atkinson TM, Ryan SJ, Bennett AV et al (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24(8):3669–3676
3. Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632
4. Basch E, Campbell A, Hudgens S et al (2020) Broadening the definition of tolerability in cancer clinical trials to capture the patient experience. Friends of Cancer, Washington, DC
5. Kim J, Singh H, Ayalew K et al (2018) Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections. Clin Cancer Res 24(8):1780–1784
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献